2mxm | pdb_00002mxm
NMR solution structure of TRTX-Tp1a from the tarantula Thrixopelma pruriens
Structural highlights
Publication Abstract from PubMedSpider venoms are a rich source of ion channel modulators with therapeutic potential. Given the analgesic potential of subtype-selective inhibitors of voltage-gated sodium (NaV) channels, we screened spider venoms for inhibitors of human NaV1.7 using a high-throughput fluorescent assay. Here, we describe the discovery of a novel NaV1.7 inhibitor, mu-TRTX-Tp1a (Tp1a), isolated from the venom of the Peruvian green-velvet tarantula Thrixopelma pruriens. Recombinant and synthetic forms of this 33-residue peptide preferentially inhibited hNav1.7 > hNav1.6 > hNav1.2 > hNav1.1 > hNav1.3 channels in fluorescent assays. NaV1.7 inhibition was diminished (IC50 11.5 nM), and the association rate decreased, for the C-terminal acid form of Tp1a compared to the native amidated form (IC50 2.1 nM), suggesting that the peptide C-terminus contributes to its interaction with hNaV1.7. Tp1a had no effect on human voltage-gated calcium channels or nicotinic acetylcholine receptors at 5 muM. Unlike most spider toxins that modulate NaV channels, Tp1a inhibited hNav1.7 without significantly altering the voltage-dependence of activation or inactivation. Tp1a proved to be analgesic by reversing spontaneous pain induced in mice by intraplantar injection in OD1, a scorpion toxin that potentiates hNav1.7. The structure of Tp1a as determined using NMR spectroscopy revealed a classical inhibitor cystine knot motif (ICK). The molecular surface of Tp1a presents a hydrophobic patch surrounded by positively charged residues, with subtle differences to other ICK spider toxins that might contribute to its different pharmacological profile. Tp1a may help guide the development of more selective and potent hNaV1.7 inhibitors for treatment of chronic pain. Identification and Characterization of ProTx-III [mu-TRTX-Tp1a], A New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula Thrixopelma Pruriens.,Cardoso FC, Dekan Z, Rosengren KJ, Erickson A, Vetter I, Deuis J, Herzig V, Alewood P, King GF, Lewis RJ Mol Pharmacol. 2015 May 15. pii: mol.115.098178. PMID:25979003[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
| ||||||||||||||||
